NCT01664910 (Clinical Trial / inotuzumab ozogamycin / CMC-544)

Study Title

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies (NCT01664910)

Trial Description

The goal of this clinical research study is to learn which dose level of inotuzumab ozogamicin (also known as CMC-544) work best when given with fludarabine and bendamustine, with or without rituximab, before a stem cell transplant.The safety of this treatment will also be studied.

Fludarabine, bendamustine, and rituximab are commonly given before stem cell transplants. These drugs are designed to kill cancerous cells and suppress your immune system in order to lower the risk of stem cell transplant rejection. Inotuzumab ozogamicin is designed to kill cancerous cells and reduce the risk of the cancer coming back.

This trial is sponsored by M.D. Anderson Cancer Center/ Pfitzer. [1]

Study Data

Study Schematic 

NCT01664910 (Clinical Trial / inotuzumab ozogamycin / CMC-544)

Click here to Return to Drug map

Last Editorial review: July 31, 2016
Information based on (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.